Agilent (NYSE:A) has always been something of an odd one out. Although the company boasts a market capitalization of approximately $10 billion, Agilent is relatively under-followed and often overlooked. Some of that is because of the unusual collection of businesses. The company has historically derived about half of its revenue from electronic test and measurement equipment and the other half from biological and chemical analysis equipment, and few analysts have expertise in both of those markets.
What may be Wall Street's pain can be a motivated investor's gain. Because Agilent does not get the close scrutiny of other names, and because there is not a small army of analysts flogging the stock to institutional clients, investors can occasionally pick these shares up on the cheap.
To read the complete piece, please go to:
http://stocks.investopedia.com/stock-analysis/2010/Agile-Agilent-A-DHR-JDSU-LIFE-TMO-WAT-CHL0818.aspx
No comments:
Post a Comment